Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2

• Published in: bioRxiv 2022-03
• Main Authors: Anglero-Rodriguez, Yesseinia I, Lempp, Florian A, Mcininch, James, Schlegel, Mark K, Brown, Christopher R, Foster, Donald J, Castoreno, Adam B, Nguyen, Tuyen, Subramanian, Megha, Montiel-Ruiz, Martin, Kaiser, Hannah, Sahakyan, Anna, Spreafico, Roberto, Svetlana Shulga Morskaya, Barry, Joseph D, Berman, Daniel, Lefebvre, Stephanie, Kasper, Anne, Racie, Timothy, Weddle, Diann, Mobley, Melissa, Rogers, Arlin, Dybowski, Joseph, Chong, Saheo, Nair, Jayprakash, Simon, Amy, Sloan, Kevin, Hwang, Seungmin, Virgin, Herbert W, Fitzgerald, Kevin, Maier, Martin A, Hinkle, Gregory, Hebner, Christy, Akinc, Akin, Jadhav, Vasant
• Format: Article
• Language: English
• Subjects: Biotechnology; Coronaviruses; Genomes; Infections; Lipophilic; Pharmacology and Toxicology; RNA-mediated interference; Severe acute respiratory syndrome coronavirus 2; siRNA; Viral infections
• ISSN: 2692-8205
• DOI: 10.1101/2022.03.20.485044

RNA interference is a natural antiviral mechanism that could be harnessed to combat SARS-CoV-2 infection by targeting and destroying the viral genome. We screened lipophilic small-interfering RNA (siRNA) conjugates targeting highly conserved regions of the SARS-CoV-2 genome and identified leads targeting outside of the spike-encoding region capable of achieving ≥3-log viral reduction. Serial passaging studies demonstrated that a two-siRNA combination prevented development of resistance compared to a single-siRNA approach. A two-siRNA combination delivered intranasally protected Syrian hamsters from weight loss and lung pathology by viral infection upon prophylactic administration but not following onset of infection. Together, the data support potential utility of RNAi as a prophylactic approach to limit SARS-CoV-2 infection that may help combat emergent variants, complement existing interventions, or protect populations where vaccines are less effective. Most importantly, this strategy has implications for developing medicines that may be valuable in protecting against future coronavirus pandemics. Competing Interest Statement All authors were employees of Alnylam Pharmaceuticals or Vir Biotechnology with salary and stock or stock options when the work was conducted. HWV is a founder of PierianDx and Casma Therapeutics. Neither company provided funding for this work or is performing related work.